SOPHiA GENETICS Announces Pricing of Initial Public Offering
July 22 2021 - 6:05PM
SOPHiA GENETICS SA, the creator of a global data pooling and
knowledge sharing platform that advances data-driven medicine,
announced today the pricing of its initial public offering of
13,000,000 ordinary shares at a price of $18 per share. The gross
proceeds from the offering, before deducting underwriting discounts
and commissions and estimated fees and offering expenses payable by
SOPHiA GENETICS SA, are expected to be approximately $234 million.
In addition, SOPHiA GENETICS SA has granted the underwriters a
30-day option to purchase up to 1,950,000 additional ordinary
shares. The ordinary shares are expected to begin trading on the
Nasdaq Global Select Market on July 23, 2021 under the symbol
“SOPH.” The offering is expected to close on July 27, 2021, subject
to customary closing conditions.
J.P. Morgan, Morgan Stanley, Cowen and Credit Suisse are acting
as joint book-running managers for the offering.
The offering is being made only by means of a prospectus. Copies
of the prospectus relating to the offering may be obtained, when
available, from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at (212) 834-4533 or by email at
prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attn:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014, by telephone at (866) 718-1649 or by email at
prospectus@morganstanley.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at (833)
297-2926 or by email at PostSaleManualRequests@broadridge.com; and
Credit Suisse Securities (USA) LLC, Attn: Prospectus Department,
6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at
(800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the U.S. Securities and
Exchange Commission. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
There is no intention to publicly offer, solicit, sell or
advertise, directly or indirectly, these securities, or invest in
securities of SOPHiA GENETICS SA, such as the ordinary shares, in,
into or from Switzerland and these securities will not be listed on
the SIX Swiss Exchange or on any other exchange or regulated
trading venue in Switzerland. The ordinary shares may not be
publicly offered, directly or indirectly, in Switzerland within the
meaning of the Swiss Financial Services Act ("FinSA"), except under
an exemption from the prospectus requirements under the FinSA. No
application has or will be made to admit the ordinary shares to
trading on any trading venue (exchange or multilateral trading
facility) in Switzerland. Neither this document nor any other
offering or marketing material relating to these securities, such
as the ordinary shares, constitutes or will constitute a prospectus
pursuant to the FinSA, and neither this document nor any other
offering or marketing material relating to the ordinary shares
constitutes a prospectus pursuant to the FinSA, and neither this
document nor any other offering or marketing material relating to
the ordinary shares may be publicly distributed or otherwise made
publicly available in Switzerland in a manner which would require
the publication of a prospectus pursuant to the FinSA.
About SOPHiA GENETICS
SOPHiA GENETICS is a healthcare technology company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
more than 780 hospital, laboratory and biopharma institutions
globally.
Media
Contact:sophiagenetics@consortpartners.com
Investor Contact:Carrie
Mendivilcarrie@gilmartinir.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024